The Physiological Effects of Visfatin on Immune Response and Inflammatory Impacts on Nephropathy

Document Type : Original Articles

Author

College of Medical and Health Technologies, Ahlulbyt University, Karbala, Iraq

Abstract

Obesity triggers the development of adipokines such as leptin, resistin, and visfatin, which have been associated with the development of diabetic nephropathy and other vascular disorders. The main purpose of the current investigation was to identify the physiological impact of visfatin on immunological response and its inflammatory effects on nephropathy. Fifty Iraqi patients with chronic kidney disease (CKD) at various stages, as described by the National Kidney Foundation (NKF) and ranging in age from 48.367.56 to 53.68 8.46 years on average were considered. Prior to the start of the investigation, informed consent was obtained from all participants, and the ethics committee approved the study. Patients were classified into two groups: Group (A) comprised patients with a GFR higher than 60 mL/minute, and Group (B) comprised patients with a GFR of less than 60 mL/min. There was no considerable variance between the groups as regards visfatin, but a highly significant correlation between serum visfatin and CRP was observed. The results of the current investigation indicated that serum visfatin levels are significantly correlated with CRP in CKD patients; it is also correlated with deterioration of kidney function. Moreover, higher visfatin levels were accompanied by increased serum triglyceride and cholesterol levels. These findings would suggest that visfatin may perform an essential function in uremia-related inflammation and may serve as a potential target for treatment and prevention of renal associated complications. Future studies may delineate whether visfatin is a marker of disease activity and severity as well as a predictor of outcome in CKD.

Keywords

Main Subjects

Article Title [French]

Les Effets Physiologiques de la Visfatine sur la Réponse Immunitaire et les Impacts Inflammatoires sur la Néphropathie

Abstract [French]

L'obésité déclenche le développement d'adipokines telles que la leptine, la résistine et la visfatine, qui ont été associées au développement de la néphropathie diabétique et d'autres troubles vasculaires. L'objectif principal de l'enquête actuelle était d'identifier l'impact physiologique de la visfatine sur la réponse immunologique et ses effets inflammatoires sur la néphropathie. Cinquante patients irakiens atteints d'insuffisance rénale chronique (IRC) à divers stades, tels que décrits par la Fondation nationale du rein (FNR) et âgés de 48.367.56 à 53.688.46 ans en moyenne ont été pris en compte. Avant le début de l'enquête, le consentement éclairé de tous les participants a été obtenu et le comité d'éthique a approuvé l'étude. Les patients ont été classés en deux groupes: le groupe (A) comprenait les patients avec un DFG supérieur à 60 ml/min, et le groupe (B) comprenait les patients avec un DFG inférieur à 60 ml/min. Il n'y avait pas de variance considérable entre les groupes en ce qui concerne la visfatine, mais une corrélation hautement significative entre la visfatine sérique et la CRP a été observée. Les résultats de l'enquête actuelle ont indiqué que les taux sériques de visfatine sont significativement corrélés avec la CRP chez les patients atteints d'IRC; ils sont également corrélés à la détérioration de la fonction rénale. De plus, des taux plus élevés de visfatine étaient accompagnés d'une augmentation des taux sériques de triglycérides et de cholestérol. Ces résultats suggèrent que la visfatine peut jouer un rôle essentiel dans l'inflammation liée à l'urémie et peut servir de cible potentielle pour le traitement et la prévention des complications rénales associées. De futures études pourraient déterminer si la visfatine est un marqueur de l'activité et de la gravité de la maladie ainsi qu'un prédicteur de l'issue de l'IRC.

Keywords [French]

  • néphropathie
  • obésité
  • visfatine
  • Adipokines
  • réponse immunitaire

References

  1. Hasegawa K. Novel tubular-glomerular interplay in diabetic kidney disease mediated by sirtuin 1, nicotinamide mononucleotide, and nicotinamide adenine dinucleotide Oshima Award Address 2017. Clin Exp Nephrol. 2019;23(8):987-94.
  2. Hognogi LD, Simiti LV. The cardiovascular impact of visfatin - an inflammation predictor biomarker in metabolic syndrome. Clujul Med. 2016;89(3):322-6.
  3. Kang YS, Lee MH, Song HK, Kim JE, Ghee JY, Cha JJ, et al. Chronic Administration of Visfatin Ameliorated Diabetic Nephropathy in Type 2 Diabetic Mice. Kidney Blood Press Res. 2016;41(3):311-24.
  4. Giri B, Dey S, Das T, Sarkar M, Banerjee J, Dash SK. Chronic hyperglycemia mediated physiological alteration and metabolic distortion leads to organ dysfunction, infection, cancer progression and other pathophysiological consequences: An update on glucose toxicity. Biomed Pharmacother. 2018;107:306-28.
  5. Wang T, He C. Pro-inflammatory cytokines: The link between obesity and osteoarthritis. Cytokine Growth Factor Rev. 2018;44:38-50.
  6. Dalamaga M, Christodoulatos GS, Mantzoros CS. The role of extracellular and intracellular Nicotinamide phosphoribosyl-transferase in cancer: Diagnostic and therapeutic perspectives and challenges. Metab. 2018;82:72-87.
  7. Ratajczak J, Joffraud M, Trammell SA, Ras R, Canela N, Boutant M, et al. NRK1 controls nicotinamide mononucleotide and nicotinamide riboside metabolism in mammalian cells. Nat Commun. 2016;7:13103.
  8. Landecho MF, Tuero C, Valenti V, Bilbao I, de la Higuera M, Fruhbeck G. Relevance of Leptin and Other Adipokines in Obesity-Associated Cardiovascular Risk. Nutrients. 2019;11(11).
  9. Marouga A, Dalamaga M, Kastania AN, Kroupis C, Lagiou M, Saounatsou K, et al. Circulating resistin is a significant predictor of mortality independently from cardiovascular comorbidities in elderly, non-diabetic subjects with chronic kidney disease. Biomark. 2016;21(1):73-9.
  10. Ren J, Wu NN, Wang S, Sowers JR, Zhang Y. Obesity cardiomyopathy: evidence, mechanisms, and therapeutic implications. Physiol Rev. 2021;101(4):1745-807.
  11. Kaminski TW, Pawlak K, Karbowska M, Mysliwiec M, Pawlak D. Indoxyl sulfate - the uremic toxin linking hemostatic system disturbances with the prevalence of cardiovascular disease in patients with chronic kidney disease. BMC Nephrol. 2017;18(1):35.
  12. Sakin A, Sahin S, Behlul A, Sumnu A, Gursu M, Sakin A, et al. The association of Visfatin levels with metabolic parameters and inflammation in diabetic nephropathy. East J Med. 2020;25(2):218-24.
  13. Mohammed RA, Ebrahem EE, Youssef E, Bayoumy ESJA. Serum visfatin as a biomarker of inflammation in patients with chronic kidney disease.AAMJ. 2012;10(3):2.
  14. Yilmaz MI, Saglam M, Carrero JJ, Qureshi AR, Caglar K, Eyileten T, et al. Serum visfatin concentration and
    endothelial dysfunction in chronic kidney disease. Nephrol Dial Transplant. 2008;23(3):959-65.
  15. Vallon V, Thomson SC. The tubular hypothesis of nephron filtration and diabetic kidney disease. Nat Rev Nephrol. 2020;16(6):317-36.
  1. Kocelak P, Olszanecka-Glinianowicz M, Owczarek A, Bozentowicz-Wikarek M, Brzozowska A, Mossakowska M, et al. Plasma visfatin/nicotinamide phosphoribosyltransferase (visfatin/NAMPT) concentration is not related to kidney function in elderly subjects. Clin Chem Lab Med. 2015;53(5):793-9.
  2. Kato A, Odamaki M, Ishida J, Hishida A. Relationship between serum pre-B cell colony-enhancing factor/visfatin and atherosclerotic parameters in chronic hemodialysis patients. Am J Nephrol. 2009;29(1):31-5.
Archives of Razi Institute
Volume 76, Issue 3
September 2021
Pages 639-647

Files

Share

How to cite

Statistics